Literature DB >> 6626415

The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man.

G Houin, F Brunner, T Nebout, M Cherfaoui, G Lagrue, J P Tillement.   

Abstract

The pharmacokinetics as well as erythrocyte and plasma protein binding of doxycycline were studied in fifteen patients with various renal function impairments after oral doxycycline polyphosphate single administration. Plasma half-life (t 1/2), area under the plasma concentration-time curve (AUC), urinary excretion, renal clearance, erythrocyte and plasma protein binding (%) were regressed vs creatinine clearance. No significant correlations were observed between t 1/2 or AUC and renal function nor plasma protein binding and plasma albumin concentrations. Significant correlations were obtained between urinary excretion, renal clearance, erythrocyte binding, plasma protein binding and creatinine clearance. Significant correlation was obtained between haematocrit and erythrocyte binding. Constancy of overall elimination parameters in renal failure is due to parallel increase in plasma free fraction of doxycycline.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6626415      PMCID: PMC1428002          DOI: 10.1111/j.1365-2125.1983.tb02157.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Doxycycline pharmacokinetics in the absence of renal function.

Authors:  A Whelton; M Schach von Wittenau; T M Twomey; W G Walker; J R Bianchine
Journal:  Kidney Int       Date:  1974-05       Impact factor: 10.612

2.  [Effect of renal insufficiency on the action of doxycycline].

Authors:  F L Laurencet; J P Fabre
Journal:  J Urol Nephrol (Paris)       Date:  1968-12

3.  The distribution of tetracyclines in tissues of dogs after repeated oral administration.

Authors:  M Schach von Wittenau; C S Delahunt
Journal:  J Pharmacol Exp Ther       Date:  1966-04       Impact factor: 4.030

4.  [Doxycycline in serum, dialysate and urine of patients with kidney damage].

Authors:  W Ritzerfeld; S Westerboer; R Geller
Journal:  Int Z Klin Pharmakol Ther Toxikol       Date:  1970-10

5.  [Doxycycline. Absorption, distribution and excretion of a new broad spectrum antibiotic in man].

Authors:  J Fabre; J S Pitton; C Virieux; F L Laurencet; J P Bernhardt; J C Godel
Journal:  Schweiz Med Wochenschr       Date:  1967-07-15

6.  [Tetracycline kinetics in man. Digestive absorption and serum concentration].

Authors:  J Fabre; E Milek; P Kalfopoulos; G Mérier
Journal:  Schweiz Med Wochenschr       Date:  1971-05-01

7.  [The pharmacokinetics of doxycycline in kidney insufficiency in geriatric patients compared to younger adults].

Authors:  C Simon; V Malerczyk; H Engelke; I Preuss; H Grahmann; K Schmidt
Journal:  Schweiz Med Wochenschr       Date:  1975-11-29

8.  Modification of the binding of sulphamidochlorobenzoic acid to human albumin by palmitic acid contamination of albumin.

Authors:  R Zini; P D'Athis; J P Tillement
Journal:  Eur J Clin Pharmacol       Date:  1977-12-16       Impact factor: 2.953

9.  Studies on the absorption and distribution of doxycycline in normal patients and in patients with severely impaired renal function.

Authors:  W A Mahon; J V Wittenberg; P G Tuffnel
Journal:  Can Med Assoc J       Date:  1970-11-07       Impact factor: 8.262

10.  Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect.

Authors:  A Yacobi; J A Udall; G Levy
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

View more
  11 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of doxycycline and minocycline.

Authors:  S Saivin; G Houin
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 3.  Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics.

Authors:  Keith A Rodvold; Rodrigo M Burgos; Xing Tan; Manjunath P Pai
Journal:  Clin Pharmacokinet       Date:  2020-04       Impact factor: 6.447

4.  Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease.

Authors:  F Keller; M Maiga; H H Neumayer; H Lode; A Distler
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

Review 5.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

6.  Pharmacokinetics of doxycycline in adults with cystic fibrosis.

Authors:  Paul M Beringer; Heather Owens; Albert Nguyen; Debbie Benitez; Adupa Rao; David Z D'Argenio
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

Review 7.  Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.

Authors:  Andrew Chou; Elwyn Welch; Andrew Hunter; Barbara W Trautner
Journal:  Drugs       Date:  2022-03-14       Impact factor: 11.431

Review 8.  Malaria prophylaxis in patients with renal impairment: a review.

Authors:  Sabine Amet; Sarah Zimner-Rapuch; Vincent Launay-Vacher; Nicolas Janus; Gilbert Deray
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

9.  Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis.

Authors:  Kathrine R Tan; Alan J Magill; Monica E Parise; Paul M Arguin
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

10.  Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.

Authors:  Mary Pulvino; Luojing Chen; David Oleksyn; Jing Li; George Compitello; Randy Rossi; Stephen Spence; Vijaya Balakrishnan; Craig Jordan; Brian Poligone; Carla Casulo; Richard Burack; Joel L Shapiro; Steven Bernstein; Jonathan W Friedberg; Raymond J Deshaies; Hartmut Land; Jiyong Zhao
Journal:  Oncotarget       Date:  2015-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.